Drugs / H1299 cell lysate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898828 | Aug 2024 | esophageal cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H1299 cell lysate | “H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections once every cycle (1 cycle=28 days) for 6 cycles (i.e., 6 vaccinations).” NCT05898828 ↗ |
| Modality | Vaccine | “H1299 cell lysate vaccine mixed with Montanide(R) ISA-51 VG adjuvant” NCT05898828 ↗ |
| Route | Subcutaneous | “H1299 cell lysate with Montanide(R) ISA-51 VG adjuvant vaccine via subcutaneous injections” NCT05898828 ↗ |